Want to see AU:IMR full AI Analyst Report?
IMR Stock Chart & Stats
AU$1.64
--
Market closed
AU$1.64
--
Day’s Range― - ―
52-Week RangeAU$1.15 - AU$2.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)287.54K
Market Cap
AU$532.77M
Enterprise ValueAU$468.83
Total Cash (Recent Filing)AU$40.81M
Total Debt (Recent Filing)AU$25.97M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Sep 01, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding320,947,020
10 Day Avg. Volume240,875
30 Day Avg. Volume287,535
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.89Price Target Upside76.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$3.42M
Bulls Say, Bears Say
Bulls Say
MRI-compatible EP Device SpecializationImricor’s focus on MRI-compatible electrophysiology systems is a durable strategic niche: MRI-guided ablation is structurally distinct from fluoroscopy and requires specialized hardware and regulatory know-how. This creates higher technical barriers to entry and positions the company to capture a growing clinical shift toward MRI-based cardiac procedures.
Equity Position Improved In 2025The move to positive shareholders’ equity materially reduces immediate solvency pressure and gives the company more financial flexibility. While not eliminating funding needs, a positive equity base improves access to capital, supports creditor confidence, and lowers near-term insolvency risk during continued commercialization.
Free Cash Flow Improved Vs 2024A reduction in negative free cash flow versus the prior year signals progress on cost structure or operational scaling. Sustained improvements can extend runway, reduce dilution risk from future financings, and demonstrate that management is making durable operational adjustments toward eventual cash generation.
Bears Say
Persistent Heavy Cash BurnConsistent, large negative operating and free cash flows create an enduring dependency on external financing. This constrains the company’s ability to invest in commercialization and R&D without dilution, raises execution risk if markets tighten, and places pressure on strategic choices over a multi‑month horizon.
Negative Gross Profit And Large Net LossesRepeated negative gross margins and severe operating losses indicate the business has not yet reached scalable unit economics. Without durable revenue growth or margin improvement, losses will likely persist, undermining long-term profitability prospects and forcing ongoing tradeoffs between growth investments and cost reduction.
High Leverage And Refinancing RiskElevated debt relative to a small equity base increases refinancing and covenant risk, especially given ongoing losses. Interest and principal obligations limit discretionary spending, raise default or dilution probabilities if new capital is required, and make capital structure management a persistent strategic constraint.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh News
IMR FAQ
What was Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price range in the past 12 months?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh lowest share price was AU$1.15 and its highest was AU$2.25 in the past 12 months.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap is AU$532.77M.
When is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date is Sep 01, 2026 which is in 40 days.
How were Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s earnings last quarter?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, beating the consensus estimate of -AU$0.033 by AU$0.033.
Is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh overvalued?
According to Wall Street analysts Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price is currently Undervalued.
Does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pay dividends?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh does not currently pay dividends.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate is -0.05.
How many shares outstanding does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh have?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 320,947,020 shares outstanding.
What happened to Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price movement after its last earnings report?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh reported an EPS of AU$0 in its last earnings report, beating expectations of -AU$0.033. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh?
Currently, no hedge funds are holding shares in AU:IMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$2.89 (76.22% Upside)
AU$2.89 (76.22% Upside)
Blogger Sentiment
Bullish
AU:IMR Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
96.47%
Trailing 12-Months
Company Description
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Earnings & Revenues
IMR Stock 12 Month Forecast
Average Price Target
AU$2.89
▲(76.22% Upside)
Technical Analysis
Impedimed Limited
―
HeraMED Ltd.
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―